INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 194 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $767,000 | -26.6% | 16,000 | -3.6% | 0.06% | -39.3% |
| Q1 2020 | $1,045,000 | -31.9% | 16,600 | +34.0% | 0.11% | 0.0% |
| Q4 2019 | $1,535,000 | +312.6% | 12,390 | +121.2% | 0.11% | +296.3% |
| Q3 2019 | $372,000 | -62.9% | 5,600 | -55.6% | 0.03% | -62.0% |
| Q2 2019 | $1,003,000 | -33.1% | 12,600 | -6.0% | 0.07% | -34.9% |
| Q1 2019 | $1,499,000 | +11.0% | 13,400 | 0.0% | 0.11% | -12.1% |
| Q4 2018 | $1,351,000 | -10.9% | 13,400 | +11.7% | 0.12% | +7.8% |
| Q3 2018 | $1,516,000 | +100.8% | 12,000 | +33.3% | 0.12% | +94.9% |
| Q2 2018 | $755,000 | – | 9,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |